Northwest Biotherapeutics, Inc (NASDAQ:NWBO) provided an update about the Company’s Phase 3 trial of DCVax®-L for Glioblastome multiforme (GBM) brain cancer (the “Trial”). …
Thursday turned out to be a nightmare for shareholders of Northwest Biotherapeutics, Inc (NASDAQ:NWBO), after the biotechnology firm announced that the Nasdaq Staff has not accepted …
After jumping 22% yesterday on no news, Northwest Biotherapeutics, Inc (NASDAQ:NWBO) announced today, along with the University Medical Center (UMC) of the Johannes Gutenberg University …
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) announced that it has entered into definitive agreements with an institutional investor to sell an aggregate of approximately $5.0 million …
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) announced that Dr. Marnix Bosch, Chief Technical Officer, today presented an updated and more detailed analysis of the Phase …
Northwest Biotherapeutics, Inc (NASDAQ:NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive …
Northwest Biotherapeutics, Inc (NASDAQ:NWBO) is up 26% in pre-market trading Tuesday, after the company provided an operations updates on its phase 1 and …
Northwest Biotherapeutics, Inc (NASDAQ:NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is expanding its Board …
Zacks Small Cap Research analyst Grant Zeng was out pounding the table on Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Monday, reiterating a Buy rating and raising the …
Fitbit Inc (NYSE:FIT) shares slipped -5.82% in pre-market trading down to $39, as worries about the health of China’s economy shook markets, hitting stocks in …
